18F‐AV‐1451 (formerly called 18F‐T807; Chien et al, 2013; Xia et al, 2013) detects AD‐type tau aggregates (Marquié et al, 2015; Smith et al, 2016a), differentiates AD patients from controls (Brier et al, 2016; Gordon et al, 2016; Johnson et al, 2016; Schöll et al, 2016; Schwarz et al, 2016) and correlates with regional changes in brain glucose metabolism in AD (Ossenkoppele et al, 2016; Smith et al, 2016b). Here, MAPT is linked to Alzheimer disease.